| Autor: |
Giunta, Emilio Francesco, Caroli, Paola, Scarpi, Emanuela, Altavilla, Amelia, Rossetti, Virginia, Marini, Irene, Celli, Monica, Casadei, Chiara, Lolli, Cristian, Schepisi, Giuseppe, Bleve, Sara, Brighi, Nicole, Cursano, Maria Concetta, Paganelli, Giovanni, Matteucci, Federica, De Giorgi, Ugo |
| Předmět: |
|
| Zdroj: |
European Journal of Nuclear Medicine & Molecular Imaging; Dec2024, Vol. 52 Issue 1, p326-334, 9p |
| Abstrakt: |
Purpose: to assess the utility of response monitoring to enzalutamide by using [68Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy. Methods: patients underwent [68Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method. Results: 69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones. Conclusions: [68Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink